UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Cannabis (marijuana): Acute intoxication

Author
George Sam Wang, MD
Section Editors
Michele M Burns, MD, MPH
Stephen J Traub, MD
Deputy Editor
James F Wiley, II, MD, MPH

INTRODUCTION

This topic discusses the epidemiology, pharmacology, toxicity, clinical manifestations, and management of acute intoxication with cannabis (marijuana).

The clinical manifestations and management of toxicity from synthetic cannabinoids, medical uses of cannabinoids, and the manifestations and treatment of cannabis use disorder are provided separately:

(See "Synthetic cannabinoids: Acute intoxication".)

(See "Cancer pain management: Adjuvant analgesics (coanalgesics)", section on 'Cannabis and cannabinoids'.)

(See "Symptom management of multiple sclerosis in adults", section on 'Cannabinoids'.)

                               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 13 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. http://www.who.int/substance_abuse/facts/cannabis/en/ (Accessed on August 11, 2016).
  2. https://www.drugabuse.gov/publications/drugfacts/high-school-youth-trends. (Accessed on August 11, 2016).
  3. Joffe A, Yancy WS, American Academy of Pediatrics Committee on Substance Abuse, American Academy of Pediatrics Committee on Adolescence. Legalization of marijuana: potential impact on youth. Pediatrics 2004; 113:e632.
  4. Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc 2012; 87:172.
  5. Committee on Substance Abuse, Committee on Adolescence, Committee on Substance Abuse Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics 2015; 135:584.
  6. http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881 (Accessed on August 11, 2016).
  7. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr 2013; 167:630.
  8. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann Emerg Med 2014; 63:684.
  9. Wang GS, Le Lait MC, Deakyne SJ, et al. Unintentional Pediatric Exposures to Marijuana in Colorado, 2009-2015. JAMA Pediatr 2016; 170:e160971.
  10. Salomonsen-Sautel S, Sakai JT, Thurstone C, et al. Medical marijuana use among adolescents in substance abuse treatment. J Am Acad Child Adolesc Psychiatry 2012; 51:694.
  11. http://www.emcdda.europa.eu/publications/country-overviews/nl (Accessed on July 01, 2014).
  12. http://www.cicad.oas.org/oid/pubs/druguse_in_americas_2011_en.pdf (Accessed on July 01, 2014).
  13. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42:327.
  14. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013; 33:195.
  15. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91:1585.
  16. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178:101.
  17. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007; 4:1770.
  18. http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php (Accessed on July 01, 2014).
  19. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005; 10 Suppl A:15A.
  20. Schwilke EW, Schwope DM, Karschner EL, et al. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009; 55:2180.
  21. Tanasescu R, Constantinescu CS. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol 2013; 9:1219.
  22. Toennes SW, Ramaekers JG, Theunissen EL, et al. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol 2008; 32:470.
  23. Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend 2009; 103:107.
  24. Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med 1982; 307:819.
  25. van der Pol P, Liebregts N, Brunt T, et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 2014; 109:1101.
  26. ElSohly MA, Mehmedic Z, Foster S, et al. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biol Psychiatry 2016; 79:613.
  27. DrugFacts: Marijuana. National Institute on Drug Abuse. January 2014 http://www.drugabuse.gov/publications/drugfacts/marijuana (Accessed on November 03, 2014).
  28. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav 2014; 39:1430.
  29. Morean ME, Kong G, Camenga DR, et al. High School Students' Use of Electronic Cigarettes to Vaporize Cannabis. Pediatrics 2015; 136:611.
  30. Hartman RL, Brown TL, Milavetz G, et al. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clin Chem 2015; 61:850.
  31. MacCoun RJ, Mello MM. Half-baked--the retail promotion of marijuana edibles. N Engl J Med 2015; 372:989.
  32. Jampel H. American glaucoma society position statement: marijuana and the treatment of glaucoma. J Glaucoma 2010; 19:75.
  33. Buys YM, Rafuse PE. Canadian Ophthalmological Society policy statement on the medical use of marijuana for glaucoma. Can J Ophthalmol 2010; 45:324.
  34. Devine ML, Dow GJ, Greenberg BR, et al. Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study. Clin Pharm 1987; 6:319.
  35. Dow GJ, Meyers FH, Stanton W, Devine ML. Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. Clin Pharm 1984; 3:14.
  36. Zuurman L, Ippel AE, Moin E, van Gerven JM. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009; 67:5.
  37. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352:1611.
  38. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:849.
  39. Linszen D, van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007; 20:116.
  40. Barkus E. High-potency cannabis increases the risk of psychosis. Evid Based Ment Health 2016; 19:54.
  41. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015; 2:233.
  42. André C, Jaber-Filho JA, Bento RM, et al. Delirium following ingestion of marijuana present in chocolate cookies. CNS Spectr 2006; 11:262.
  43. Appelboam A, Oades PJ. Coma due to cannabis toxicity in an infant. Eur J Emerg Med 2006; 13:177.
  44. Bonkowsky JL, Sarco D, Pomeroy SL. Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care 2005; 21:527.
  45. Carstairs SD, Fujinaka MK, Keeney GE, Ly BT. Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine. J Emerg Med 2011; 41:e69.
  46. Macnab A, Anderson E, Susak L. Ingestion of cannabis: a cause of coma in children. Pediatr Emerg Care 1989; 5:238.
  47. Weinberg D, Lande A, Hilton N, Kerns DL. Intoxication from accidental marijuana ingestion. Pediatrics 1983; 71:848.
  48. Heizer JW, Borgelt LM, Bashqoy F, et al. Marijuana Misadventures in Children: Exploration of a Dose-Response Relationship and Summary of Clinical Effects and Outcomes. Pediatr Emerg Care 2016.
  49. Caldicott DG, Holmes J, Roberts-Thomson KC, Mahar L. Keep off the grass: marijuana use and acute cardiovascular events. Eur J Emerg Med 2005; 12:236.
  50. Deharo P, Massoure PL, Fourcade L. Exercise-induced acute coronary syndrome in a 24-year-old man with massive cannabis consumption. Acta Cardiol 2013; 68:425.
  51. Bachs L, Mørland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124:200.
  52. Kim HS, Anderson JD, Saghafi O, et al. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med 2015; 22:694.
  53. Blackstone M, Callahan J. An unsteady walk in the park. Pediatr Emerg Care 2008; 24:193.
  54. Le Garrec S, Dauger S, Sachs P. Cannabis poisoning in children. Intensive Care Med 2014; 40:1394.
  55. Croche Santander B, Alonso Salas MT, Loscertales Abril M. [Accidental cannabis poisoning in children: report of four cases in a tertiary care center from southern Spain]. Arch Argent Pediatr 2011; 109:4.
  56. Renier S, Messi G, Orel P. [Acute cannabis poisoning in a female child]. Minerva Pediatr 1994; 46:335.
  57. Caponnetto P, Auditore R, Russo C, et al. "Dangerous relationships": asthma and substance abuse. J Addict Dis 2013; 32:158.
  58. Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc 2013; 10:239.
  59. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103:2805.
  60. Jouanjus E, Lapeyre-Mestre M, Micallef J, French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications*. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014; 3:e000638.
  61. Frost L, Mostofsky E, Rosenbloom JI, et al. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J 2013; 165:170.
  62. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.
  63. Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on aircraft pilot performance. Aviat Space Environ Med 1991; 62:221.
  64. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344:e536.
  65. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction 2016; 111:1348.
  66. Leggett T, United Nations Office on Drugs and Crime. A review of the world cannabis situation. Bull Narc 2006; 58:1.
  67. Grauwiler SB, Drewe J, Scholer A. Sensitivity and specificity of urinary cannabinoid detection with two immunoassays after controlled oral administration of cannabinoids to humans. Ther Drug Monit 2008; 30:530.
  68. Department of Health and Human Services: Substance Abuse and Mental Health Services Administration: Mandatory Guidelines for Federal Workplace Drug Testing Programs. Fed Regist 2008; 73:71858.
  69. Cone EJ, Johnson RE, Darwin WD, et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol 1987; 11:89.
  70. Mørland J, Bugge A, Skuterud B, et al. Cannabinoids in blood and urine after passive inhalation of Cannabis smoke. J Forensic Sci 1985; 30:997.
  71. Law B, Mason PA, Moffat AC, et al. Passive inhalation of cannabis smoke. J Pharm Pharmacol 1984; 36:578.
  72. Mulé SJ, Lomax P, Gross SJ. Active and realistic passive marijuana exposure tested by three immunoassays and GC/MS in urine. J Anal Toxicol 1988; 12:113.
  73. Röhrich J, Schimmel I, Zörntlein S, et al. Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. J Anal Toxicol 2010; 34:196.
  74. Schwartz RH, Hawks RL. Laboratory detection of marijuana use. JAMA 1985; 254:788.
  75. ElSohly MA, deWit H, Wachtel SR, et al. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 2001; 25:565.
  76. Oosthuizen NM, Laurens JB. Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol. Ann Clin Biochem 2012; 49:194.
  77. ElSohly MA. Practical challenges to positive drug tests for marijuana. Clin Chem 2003; 49:1037.
  78. Cotten SW, Duncan DL, Burch EA, et al. Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay. Clin Biochem 2012; 45:605.
  79. Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol 2014; 38:387.
  80. Smith-Kielland A, Skuterud B, Mørland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 1999; 23:323.
  81. Sun S, Zimmermann AE. Cannabinoid hyperemesis syndrome. Hosp Pharm 2013; 48:650.
  82. Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med 2013; 31:1003.e5.
  83. Witsil JC, Mycyk MB. Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome. Am J Ther 2014.
  84. Lapoint J. Capsaicin cream for treatment of cannabinoid hyperemesis syndrome. American College of Medical Toxicology Annual Scientific Meeting abstracts. Abstract 51. 2014. Available at http://www.acmt.net/Abstracts_41-60.html#fiftyone (accessed August 30, 2016).